Related Experiment Video

Updated: Jul 20, 2026

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

Mycophenolate mofetil attenuates pulmonary arterial hypertension in rats

Chihiro Suzuki1, Masafumi Takahashi, Hajime Morimoto

  • 1Division of Cardiovascular Sciences, Department of Organ Regeneration, Shinshu University Graduate School of Medicine, Matsumoto, Japan.

Biochemical and Biophysical Research Communications
|September 8, 2006
PubMed

Insights

Mycophenolate mofetil (MMF) reduced key markers of pulmonary arterial hypertension (PAH) in rats. This immunosuppressant shows potential for treating PAH by inhibiting inflammation and cell proliferation.

Area of Science:

  • Cardiovascular Research
  • Immunology
  • Pharmacology

Background:

  • Pulmonary arterial hypertension (PAH) involves smooth muscle cell proliferation and pulmonary arteriole occlusion.
  • PAH leads to right ventricular (RV) hypertrophy and is often fatal.

Purpose of the Study:

  • To investigate if mycophenolate mofetil (MMF) can prevent monocrotaline (MCT)-induced PAH in rats.
  • To elucidate the mechanisms by which MMF may affect PAH development.

Main Methods:

  • Rats were induced with MCT to develop PAH.
  • MMF treatment was administered, and its effects on RV systolic pressure, RV hypertrophy, and pulmonary artery medial thickness were assessed.
  • Proliferating cell nuclear antigen (PCNA), macrophage infiltration, P-selectin, and interleukin-6 expression were analyzed.
  • In vitro studies examined the effect of mycophenolic acid (MPA) on human pulmonary arterial smooth muscle cell (SMC) proliferation.

Main Results:

  • MMF significantly decreased RV systolic pressure and RV hypertrophy.
  • MMF reduced medial thickness of pulmonary arteries and inhibited PCNA-positive cells.
  • MMF suppressed macrophage infiltration and the expression of P-selectin and interleukin-6.
  • Mycophenolic acid (MPA) dose-dependently inhibited human pulmonary arterial SMC proliferation in vitro.

Conclusions:

  • MMF attenuates the development of PAH in a rat model.
  • MMF's therapeutic effects are attributed to its anti-inflammatory and anti-proliferative properties.
  • Immunosuppressants like MMF may offer a novel therapeutic strategy for PAH treatment.

More Related Videos

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension09:40

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...